Nanobiotix Closes $98.6M Global Offering, Including Full Over-Allotment Exercise

summarizeSummary

Nanobiotix announced the closing of its global offering, raising approximately $98.6 million, which included the full exercise of the underwriters' over-allotment option.

check_boxKey Events

• Global Offering Closed

  Nanobiotix successfully closed its global offering on May 26, 2026, raising approximately $98.6 million. This finalizes the capital raise announced on May 21, 2026.

• Over-Allotment Option Fully Exercised

  The underwriters fully exercised their option to purchase an additional 33,805 American Depositary Shares (ADSs), demonstrating strong investor demand for the offering.

• Offering Details and Pricing

  The offering included 225,373 ADSs, 1,959,289 ordinary shares, and 345,099 pre-funded warrants. The ADSs were priced at $38.98 each, corresponding to €33.60 per ordinary share, representing a modest discount to the current market price.

• Extended Cash Runway

  The proceeds from this significant capital raise are intended to extend the company's cash runway, supporting ongoing clinical development and operational needs.

auto_awesomeAnalysis

Nanobiotix has successfully closed its global offering, raising approximately $98.6 million. This capital infusion is substantial for a life sciences company, providing critical funding to extend its cash runway and advance its clinical pipeline. The offering was oversubscribed, and the underwriters fully exercised their over-allotment option, indicating strong investor demand and confidence following recent positive clinical and regulatory updates. While dilutive, the successful execution of this capital raise at a modest discount to the current market price is a positive signal for the company's financial stability and ability to fund its strategic initiatives.